Volume 48/Number 4/Abstract 01
Acta Parasitologica Homepage
Tables of Contents
Volume 48 Tables of Contents

Acta Parasitologica, Vol.48, No. 4, 2003, 239-245
Halina Wedrychowicz(1,2)* and Marcin Wisniewski(2) - Progress in development of vaccines against most important gastrointestinal helminth parasites of humans and animals

(1)Department of Molecular Biology, W. Stefanski Institute of Parasitology PAS, 51/55 Twarda Street, 00-818 Warszawa; (2)Department of Parasitology, Faculty of Veterinary Medicine, Warsaw Agriculture University, 8 Ciszewskiego Street, 02-786 Warszawa; Poland
*Corresponding author: halinwe@twarda.pan.pl

Among many vaccine approaches developed against gastrointestinal helminths in the recent years, parenteral vaccination and use of recombinant helminth antigens expressed in various expression systems have been a major focus. Significant progress has been made towards cloning of protective worm antigens. The recombinant proteins have several benefits over classic vaccine technologies, including increased safety, economy, stability and versatility. Moreover, the identification of site and developmental stage of the parasite in which the expression of genes encoding for potential vaccine antigen become possible using a variety of molecular techniques including hybridization in situ, expressed sequence tags analysis or cDNA microarray technology. Unfortunately, in the research reported so far little attention has been paid to oral vaccination, which may be of particular importance for the development of protective immunity against enteric parasites. The biggest obstacles to vaccine production at present time are: lack of an efficient expression system, which could guarantee proper post-translational modifications of recombinant helminth antigens as well as lack of efficient mucosal delivery systems. These obstacles will be possibly successfully overcome by use of transgenic plants both for the antigen expression and as adjuvants.

KEY WORDS: Helminths, vaccines, recombinant antigens, DNA vaccines, oral vaccines

Page compiled by M. Bultowicz. Last modification: 21-01-2004